



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)  
from Capital District Health Authority/*Cancer Care Nova Scotia***

**Guidelines for the Role of Docetaxel / Cyclophosphamide as Adjuvant Therapy for  
Breast Cancer**

**Approved Use:**

- **Docetaxel plus Cyclophosphamide (TC):** In combination (TC) as an adjuvant therapy option in patients who have documented evidence of Stage I to Stage III operable invasive breast cancer with complete surgical excision of the primary tumour and who are candidates for systemic chemotherapy for low – moderate risk disease.
- This policy recommendation represents a **new guideline document** and a restriction of **Docetaxel plus Cyclophosphamide (TC)** as adjuvant therapy to include Stage I to Stage III operable invasive breast cancer patients who have had complete surgical excision of the primary tumour and who are candidates for systemic chemotherapy for low – moderate risk disease.